Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2018

20.02.2018 | Clinical Study

Incidence and survival of gliomatosis cerebri: a population-based cancer registration study

verfasst von: Marios K. Georgakis, Dimitrios Spinos, Apostolos Pourtsidis, Amanda Psyrri, Ioannis G. Panourias, Spyridon Sgouros, Eleni Th. Petridou

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Gliomatosis cerebri (GC) comprises a rare widespread infiltrating growth pattern of diffuse gliomas. We explored the incidence patterns and survival rates of GC in a population-based registration sample from the Surveillance, Epidemiology and End, Results database (1973–2012). GC cases (n = 176) were identified based on their International Classification of Diseases in Oncology (ICD-O-3) morphology code (9381). We calculated age-adjusted incidence rates (AIR) and evaluated temporal trends. Survival was assessed with Kaplan–Meier curves and Cox regression models. The annual AIR of GC was 0.1/million. We noted increasing trends in the preceding registration years (1973–2002; annually, + 7%) and a tendency of clinical/radiological approaches to substitute the gold-standard histological assessment for diagnosis. GC was diagnosed in the entire age spectrum (range 1–98 years), but higher incidence rates (0.43/million) were noted among the elderly (≥ 65 years). A slight male preponderance was identified (male-to-female ratio: 1.4). Median overall survival was 9 months with a 5 year survival rate of 18%. Increasing age, primary tumor location not restricted to the cerebral hemispheres and rural residence at diagnosis were identified as negative prognostic factors, whereas receipt of radiotherapy, surgical treatment, race and method of diagnosis were not associated with outcome. This first comprehensive overview of GC epidemiology exemplifies the rarity of the disease, provides evidence for male preponderance and increased incidence among the elderly and shows lower survival rates compared to the published single center reports. Expansion of registration to histological and molecular characteristics would allow emergence of clinical prognostic factors at the population level.
Literatur
2.
Zurück zum Zitat Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: a consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63:2072–2077. https://doi.org/10.1002/pbc.26169 CrossRefPubMed Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: a consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63:2072–2077. https://​doi.​org/​10.​1002/​pbc.​26169 CrossRefPubMed
3.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization histological classification of tumours of the central nervous system. IARC, Lyon Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization histological classification of tumours of the central nervous system. IARC, Lyon
5.
Zurück zum Zitat Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bahr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131:309–319. https://doi.org/10.1007/s00401-015-1495-z CrossRefPubMed Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bahr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131:309–319. https://​doi.​org/​10.​1007/​s00401-015-1495-z CrossRefPubMed
12.
Zurück zum Zitat Surveillance, Epidemiology, End Results (SEER) Program (http://www.seer.cancer.gov) Research data (1973–2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission Surveillance, Epidemiology, End Results (SEER) Program (http://​www.​seer.​cancer.​gov) Research data (1973–2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission
13.
Zurück zum Zitat Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D (2000) International classification of diseases for oncology. 3rd edn. WHO, Geneva Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D (2000) International classification of diseases for oncology. 3rd edn. WHO, Geneva
15.
Zurück zum Zitat Boyle P, Parkin DM (1991) Statistical methods for registries In: International Agency for Research on Cancer (IARC) Cancer Registration: Principles and Methods IARC Scientific Publication No 95. Lyon, pp 126–158 Boyle P, Parkin DM (1991) Statistical methods for registries In: International Agency for Research on Cancer (IARC) Cancer Registration: Principles and Methods IARC Scientific Publication No 95. Lyon, pp 126–158
16.
Zurück zum Zitat Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62 https://doi.org/10.1093/neuonc/nov189 CrossRef Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62 https://​doi.​org/​10.​1093/​neuonc/​nov189 CrossRef
18.
Zurück zum Zitat Georgakis MK, Karalexi MA, Kalogirou EI, Ryzhov A, Zborovskaya A, Dimitrova N, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Agius D, Florea M, Coza D, Bouka E, Bourgioti C, Dana H, Hatzipantelis E, Moschovi M, Papadopoulos S, Sfakianos G, Papakonstantinou E, Polychronopoulou S, Sgouros S, Stefanaki K, Stiakaki E, Strantzia K, Zountsas B, Pourtsidis A, Patsouris E, Petridou ET (2017) Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. J Neurooncol 131:163–175. https://doi.org/10.1007/s11060-016-2284-9 CrossRefPubMed Georgakis MK, Karalexi MA, Kalogirou EI, Ryzhov A, Zborovskaya A, Dimitrova N, Eser S, Antunes L, Sekerija M, Zagar T, Bastos J, Agius D, Florea M, Coza D, Bouka E, Bourgioti C, Dana H, Hatzipantelis E, Moschovi M, Papadopoulos S, Sfakianos G, Papakonstantinou E, Polychronopoulou S, Sgouros S, Stefanaki K, Stiakaki E, Strantzia K, Zountsas B, Pourtsidis A, Patsouris E, Petridou ET (2017) Incidence, time trends and survival patterns of childhood pilocytic astrocytomas in Southern-Eastern Europe and SEER, US. J Neurooncol 131:163–175. https://​doi.​org/​10.​1007/​s11060-016-2284-9 CrossRefPubMed
24.
Zurück zum Zitat Bendszus M, Warmuth-Metz M, Klein R, Burger R, Schichor C, Tonn JC, Solymosi L (2000) MR spectroscopy in gliomatosis cerebri. AJNR Am J Neuroradiol 21:375–380PubMed Bendszus M, Warmuth-Metz M, Klein R, Burger R, Schichor C, Tonn JC, Solymosi L (2000) MR spectroscopy in gliomatosis cerebri. AJNR Am J Neuroradiol 21:375–380PubMed
25.
Zurück zum Zitat Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH (2003) Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 56:1137–1146CrossRefPubMed Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH (2003) Gliomatosis cerebri: improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 56:1137–1146CrossRefPubMed
28.
Zurück zum Zitat Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73–82CrossRefPubMed Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73–82CrossRefPubMed
29.
Zurück zum Zitat Glas M, Bahr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nagele T, Reifenberger G, Weller M, Herrlinger U, Neuro-Oncology Group of the German Cancer Society (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70:445–453 https://doi.org/10.1002/ana.22478 CrossRefPubMed Glas M, Bahr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nagele T, Reifenberger G, Weller M, Herrlinger U, Neuro-Oncology Group of the German Cancer Society (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70:445–453 https://​doi.​org/​10.​1002/​ana.​22478 CrossRefPubMed
31.
Zurück zum Zitat Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219–224. https://doi.org/10.1007/s11060-011-0587-4 CrossRefPubMed Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M (2011) Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol 105:219–224. https://​doi.​org/​10.​1007/​s11060-011-0587-4 CrossRefPubMed
33.
Zurück zum Zitat Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF group (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 63:270–275CrossRefPubMed Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, Gervais H, Laigle F, Carpentier A, Mokhtari K, Taillandier L, Chinot O, Duffau H, Honnorat J, Hoang-Xuan K, Delattre JY, ANOCEF group (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 63:270–275CrossRefPubMed
36.
Zurück zum Zitat Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Themistocleous M, Tolia M, Tzanis S, Alexiou GA, Papanikolaou PG, Nomikos P, Kantzanou M, Dessypris N, Pourtsidis A, Petridou ET (2017) Malignant central nervous system tumors among adolescents and young adults (15–39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: mortality and survival patterns. Cancer. https://doi.org/10.1002/cncr.30884 PubMed Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Themistocleous M, Tolia M, Tzanis S, Alexiou GA, Papanikolaou PG, Nomikos P, Kantzanou M, Dessypris N, Pourtsidis A, Petridou ET (2017) Malignant central nervous system tumors among adolescents and young adults (15–39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: mortality and survival patterns. Cancer. https://​doi.​org/​10.​1002/​cncr.​30884 PubMed
Metadaten
Titel
Incidence and survival of gliomatosis cerebri: a population-based cancer registration study
verfasst von
Marios K. Georgakis
Dimitrios Spinos
Apostolos Pourtsidis
Amanda Psyrri
Ioannis G. Panourias
Spyridon Sgouros
Eleni Th. Petridou
Publikationsdatum
20.02.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2802-z

Weitere Artikel der Ausgabe 2/2018

Journal of Neuro-Oncology 2/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.